Drugs / QUC398
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05462990 | Nov 2022 → Aug 2024 | osteoarthritis, knee | Novartis Pharmaceuticals | Terminated | Missed primary Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QUC398 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05462990 ↗ |
| Route | Subcutaneous | “subcutaneous injections of QUC398 300 mg vs placebo every 4 weeks (q4w)” NCT05462990 ↗ |